Can Samsung Bioepis reshape Europe’s retinal disease biosimilar market with OPUVIZ?
Find out how Samsung Bioepis’ OPUVIZ launch could reshape Europe’s aflibercept biosimilar market and ophthalmology access.
Inside Bayer’s $2.45bn push to defend its ophthalmology franchise
Eylea is under pressure. Bayer’s $2.45bn Perfuse bet tests whether PER-001 can carry its next ophthalmology growth story.